USPTO Examiner BUNNER BRIDGET E - Art Unit 1647

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19006997CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USEDecember 2024July 2025Allow610NoNo
18942121TNF-ALPHA VARIANT FUSION MOLECULESNovember 2024July 2025Allow811NoNo
18651002NOTCH4 ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATING AIRWAY INFLAMMATIONApril 2024December 2024Allow810NoNo
18619759TNFR2 Agonists with Improved StabilityMarch 2024September 2024Allow610YesNo
18695013COLLAGEN HYDROLYSATE FOR USE IN PREVENTION AND/OR TREATMENT OF POST INTENSIVE CARE SYNDROME (PICS)March 2024December 2024Allow901YesNo
18587502BISPECIFIC ANTIBODY THAT BINDS TO CD116 AND CD131February 2024August 2024Allow610YesNo
18496397Serum Albumin-Binding Fibronectin Type III DomainsOctober 2023January 2026Allow2710NoNo
18474781TREATMENTS ADMINISTERING CHIMERIC IGG FC RECEPTOR COMPRISING AN EXTRACELLULAR DOMAIN OF CD64September 2023December 2025Allow2611NoNo
18470745CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USESeptember 2023October 2025Allow2410YesNo
18458692CD47 BLOCKADE THERAPY WITH CD38 ANTIBODYAugust 2023January 2026Abandon2810YesNo
18337875HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAMEJune 2023March 2025Allow2100NoNo
18327456MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENTJune 2023October 2025Allow2810NoNo
18321249Anti-Jagged Antibodies and Methods of UseMay 2023May 2025Abandon2401NoNo
18195184METHODS FOR TREATING DRUG RESISTANT CANCERSMay 2023January 2026Allow3211NoNo
18312045INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOFMay 2023May 2025Abandon2410NoNo
18296510METHODS AND COMPOSITIONS FOR IMMUNOMODULATIONApril 2023May 2025Allow2510NoNo
18295631EXOSOME FOR STIMULATING T CELL AND PHARMACEUTICAL USE THEREOFApril 2023October 2024Allow1800NoNo
18191712NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIESMarch 2023January 2026Abandon3421NoNo
18185443VEGFR Fusion Protein Pharmaceutical CompositionMarch 2023February 2025Allow2310NoNo
18121468Hematopoietic Stem Cell EngraftmentMarch 2023February 2026Allow3510NoNo
18183804METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATIONMarch 2023April 2025Allow2511NoNo
18182829HUMAN OTIC PROGENITOR IDENTIFICATION AND ISOLATIONMarch 2023September 2024Allow1810NoNo
18025398HIGH-ACTIVITY BLOOD COAGULATION FACTOR XI MUTANT ALA570THRMarch 2023February 2026Allow3610NoNo
18041845A FUSION PROTEIN COMPRISING AN ANTIGEN BINDING DOMAIN AND A CYTOKINE TRIMER DOMAINFebruary 2023June 2024Allow1610NoNo
18167265AMELIORATION AND TREATMENT OF INFARCTION DAMAGEFebruary 2023March 2026Abandon3710NoNo
18107386PREFILLED SYRINGE WITH PEGFILGRASTIM HAVING OPTIMIZED DOSE AND METHODS RELATED THERETOFebruary 2023February 2025Allow2511NoNo
18006370IL27RAlpha Binding Molecules and Methods of UseJanuary 2023July 2024Allow1821YesNo
18014288Extracellular Vesicles and Compositions ThereofJanuary 2023March 2026Allow3810NoNo
18069704ANTIBODY CONSTRUCTS FOR DLL3 AND CD3December 2022July 2025Allow3111NoNo
18061066METHODS RELATED TO THE TREATMENT OF IGA NEPHROPATHYDecember 2022January 2026Allow3710YesNo
17992529Blood Biomarkers and Diagnostic Methods for Small Vessel DiseasesNovember 2022August 2024Allow2110NoNo
17924427INHIBITION OF SARS-COV-2 INFECTION THROUGH SYNDECANSNovember 2022February 2026Abandon3901NoNo
18047039ANTI-HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOFOctober 2022November 2023Allow1310NoNo
17934064BINDING MOLECULES AGAINST BCMA AND USES THEREOFSeptember 2022December 2024Allow2701YesNo
17933229NOVEL ANTI-PAD4 ANTIBODYSeptember 2022June 2025Allow3310NoNo
17931049OPTIMIZED ANTI-TL1A ANTIBODIESSeptember 2022October 2024Abandon2510NoNo
17798481METHODS OF USE OF SOLUBLE CD24 FOR TREATING SARS-COV-2 INFECTIONAugust 2022January 2026Abandon4110NoNo
17816823IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIESAugust 2022February 2025Allow3120NoNo
17796307METHODS OF USE OF SOLUBLE CD24 FOR TREATING VIRAL PNEUMONIAJuly 2022December 2025Abandon4110NoNo
17792608METHOD OF PRODUCING ADM COLLAGEN FIBER, ADM COLLAGEN FIBER PRODUCED USING METHOD, AND APPARATUS FOR PRODUCING ADM COLLAGEN FIBERJuly 2022February 2026Allow4311NoNo
17846950TREATMENT FOR PRIMARY AMYLOIDOSIS WITH ANTI-BCMA BINDING PROTEINJune 2022October 2024Allow2810NoNo
17841704METHODS OF PROGNOSIS AND TREATMENTJune 2022October 2024Allow2811NoNo
17841595PROTEOLYTICALLY CLEAVABLE CHIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFJune 2022March 2025Allow3320NoNo
17832654METHODS OF RISK ASSESSMENT AND DISEASE CLASSIFICATIONJune 2022November 2025Abandon4110NoNo
17663260VEGFR Fusion Protein Pharmaceutical CompositionMay 2022March 2023Allow1020NoNo
17738620Interleukin-4 Receptor-Binding Fusion Proteins and Uses ThereofMay 2022July 2025Allow3910NoNo
17733640COMPOSITIONS AND METHODS FOR ENHANCING INNATE IMMUNITY IN A SUBJECT FOR TREATMENT OF INFECTIONS AND CANCER AND OTHER ACUTE AND CHRONIC CONDITIONS OF THE EYEApril 2022August 2025Allow4020NoNo
17731976NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSINApril 2022May 2023Allow1311NoNo
17732420CD137 BINDING FIBRONECTIN TYPE III DOMAINSApril 2022November 2024Allow3121NoNo
17717200EARLY DIAGNOSIS OF INFECTIONSApril 2022March 2024Allow2310NoNo
17767606Anti-Chemokine Like Receptor 1 Humanized Antibodies and Their Therapeutic ApplicationsApril 2022September 2025Allow4210NoNo
17716630METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORSApril 2022January 2025Allow3321NoNo
17716636METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORSApril 2022December 2025Allow4441YesNo
17710559Hemostatic TextileMarch 2022December 2025Allow4410YesNo
17701372SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAYMarch 2022December 2024Allow3221NoNo
17697070S-LAYER PROTEIN 2D LATTICE COUPLED DETERGENT-FREE GPCR BIOELECTRONIC INTERFACES, DEVICES, AND METHODS FOR USE THEREOFMarch 2022November 2025Abandon4410NoNo
17695769CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGENMarch 2022September 2023Allow1800NoNo
17642923NUCLEIC ACID CONSTRUCT THAT ENCODES CHIMERIC RHODOPSINMarch 2022December 2025Allow4520NoNo
17694541COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINSMarch 2022September 2025Abandon4210NoNo
17686453MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENTMarch 2022June 2024Allow2711NoNo
17686536ANTI-IL-31RA ANTIBODY-CONTAINING FORMULATIONSMarch 2022August 2024Allow2910NoNo
17682922HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOFFebruary 2022March 2024Allow2511NoNo
17680719MEDICINE FOR TREATING CANCER BY ADMINISTERING A TOLL-LIKE RECEPTOR AGONIST AND LAG-3 IgG FUSION PROTEINFebruary 2022May 2023Allow1400NoNo
17672889ANTI-JAGGED1 ANTIGEN BINDING PROTEINSFebruary 2022September 2023Allow1910NoNo
17634120NOVEL COMPOSITION COMPRISING ANTIBODIESFebruary 2022December 2025Abandon4610NoNo
17665909ANTI-CD40 ANTIBODIESFebruary 2022January 2026Abandon4710NoNo
17573991METHODS OF ADMINISTERING ANTI-IL31A ANTIBODY-CONTAINING FORMULATIONSJanuary 2022March 2023Allow1400YesNo
17569261COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINEJanuary 2022September 2024Allow3311YesNo
17563846HUMANIZED ANTIBODY SPECIFIC FOR CD22 AND CHIMERIC ANTIGEN RECEPTOR USING THE SAMEDecember 2021November 2024Allow3520YesNo
17561606COMPOSITIONS COMPRISING ALBUMIN-FMS-LIKE TYROSINE KINASE 3 LIGAND FUSION PROTEINS AND USES THEREOFDecember 2021March 2025Allow3920YesYes
17557654PROTEASE-ACTIVATING CD45-GATE CARDecember 2021April 2025Allow4011NoNo
17555357T Cell ModulatorDecember 2021October 2023Abandon2210NoNo
17552841A METHOD FOR TREATING DISEASE USING FOXP3+CD4+ T CELLSDecember 2021June 2022Allow630YesNo
17616497USE OF CD9 AS A BIOMARKER AND AS A BIOTARGET IN GLOMERULONEPHRITIS OR GLOMERULOSCLEROSISDecember 2021September 2025Allow4611NoNo
17540947ANTI-BCMA CHIMERIC ANTIGEN RECEPTORSDecember 2021January 2024Allow2611NoNo
17526883ANTI-TLR4 ANTIBODIES AND USES THEREOFNovember 2021October 2023Abandon2310NoNo
17450282ANTI-NOTCH3 ANTIBODYOctober 2021February 2025Allow4040NoNo
17493938PROTEIN-BASED PURIFICATION MATRICES AND METHODS OF USING THE SAMEOctober 2021November 2022Allow1330YesNo
17489391FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITYSeptember 2021June 2024Abandon3311NoNo
17441708ANTI-EGFRVIII ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOFSeptember 2021October 2025Allow4920NoNo
17472004FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERSSeptember 2021September 2024Abandon3701NoNo
17435325ENGINEERED CD47 EXTRACELLULAR DOMAIN FOR BIOCONJUGATIONAugust 2021February 2026Allow5311NoNo
17397447Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal CancerAugust 2021July 2024Allow3621NoNo
17397287INTERLEUKIN-4 RECEPTOR-BINDING FUSION PROTEINS AND USES THEREOFAugust 2021January 2024Abandon3011NoNo
17396792METHODS AND REAGENTS FOR MODULATING MACROPHAGE PHENOTYPEAugust 2021February 2024Allow3010NoNo
17396351Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide AgonistAugust 2021June 2024Allow3411NoNo
17429093A METHOD FOR THE TREATMENT OR PROPHYLAXIS OF CANCER BY TARGETING THE EXTRACELLULAR PORTION OF KERATIN 14 (KRT14) RESIDING ON CANCER CELLSAugust 2021March 2026Allow5521NoNo
17427581HALF-LIFE EXTENDED IMMTAC BINDING CD3 AND A HLA-A*02 RESTRICTED PEPTIDEJuly 2021June 2025Abandon4611NoNo
17423999ANTI-ELASTIN ANTIBODIES AND METHODS OF USEJuly 2021March 2025Allow4411YesNo
17376233ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF PYODERMA GANGRENOSUMJuly 2021August 2024Allow3711NoNo
17377297NUCLEIC ACID FOR TREATING MITE ALLERGYJuly 2021December 2021Allow510YesNo
17372575PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONSJuly 2021March 2024Allow3210NoNo
17415348Combination Treatments Of Cancer Comprising A TLR AgonistJune 2021February 2026Abandon5621NoNo
17346421ANTI-IL31RA ANTIBODY-CONTAINING FORMULATIONSJune 2021November 2021Allow500NoNo
17413045ANTI-HUMAN INTERLEUKIN 5(IL-5) MONOCLONAL ANTIBODY AND USE THEREOFJune 2021April 2025Abandon4601NoNo
17312590IMMUNOHISTOCHEMICAL STAINING FOR GSK-3June 2021September 2025Abandon5111NoNo
17299239REGULATABLE CELL SURFACE RECEPTORS AND RELATED COMPOSITIONS AND METHODSJune 2021June 2025Allow4811YesNo
17330716COMBINATION THERAPY FOR TREATMENT OF DISEASEMay 2021December 2023Abandon3110NoNo
17320128ANTI-JAGGED1 ANTIGEN BINDING PROTEINSMay 2021September 2023Allow2911NoNo
17317789Methods for Treating Multiple MyelomaMay 2021November 2023Allow3010YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BUNNER, BRIDGET E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
11
Examiner Affirmed
7
(63.6%)
Examiner Reversed
4
(36.4%)
Reversal Percentile
57.4%
Higher than average

What This Means

With a 36.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
93
Allowed After Appeal Filing
20
(21.5%)
Not Allowed After Appeal Filing
73
(78.5%)
Filing Benefit Percentile
28.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BUNNER, BRIDGET E - Prosecution Strategy Guide

Executive Summary

Examiner BUNNER, BRIDGET E works in Art Unit 1647 and has examined 1,142 patent applications in our dataset. With an allowance rate of 53.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner BUNNER, BRIDGET E's allowance rate of 53.8% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BUNNER, BRIDGET E receive 1.56 office actions before reaching final disposition. This places the examiner in the 29% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BUNNER, BRIDGET E is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +30.2% benefit to allowance rate for applications examined by BUNNER, BRIDGET E. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.0% of applications are subsequently allowed. This success rate is in the 50% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 52.9% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.4% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 74.4% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.4% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.2% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.